WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
CELL AND GENE THERAPY
Anuva and Helix | August 30, 2022
Anuva enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States.
Anuva will be generating new knowledge on health and disease, directly applicable to treatments, on diverse under-represented populations to advance drug discovery through the identification of novel targ...
CELL AND GENE THERAPY, MEDTECH
Nkarta, Inc. | December 06, 2022
Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma.
Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...
ABC | May 19, 2022
Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...
Lysando AG and Amicogen Inc. | October 19, 2022
Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea.
In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE